A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer

作者：Chenyu Mao, Ye He, Nong Xu, Haijiao Yan, Ningling Zhang, Gang Cheng, Hua Jiang, Min‐Bin Chen, Yong Chen, Xiaoguang Wang, Yulan Gu, Peng Shen, Guifang Zhang, Jun Yan, Zhe Yang, Lifang Ding, Zhengxiang Han, Zhanggui Wang, Junqi Zhang, Weie Zheng, Jufeng Wang, Shukui Qin · 发表于：Immunity Inflammation and Disease · 年份：2024 · DOI：10.1002/iid3.1348 · 被引用次数：4 · 研究领域：Neutropenia and Cancer Infections、Blood disorders and treatments、Colorectal Cancer Treatments and Studies

BACKGROUND: Mecapegfilgrastim, a long-acting granulocyte-colony stimulating factor has been approved for reducing the incidence of infection, particularly febrile neutropenia (FN), in China. OBJECTIVE: We conducted a multicenter prospective observational study to examine the safety and effectiveness of mecapegfilgrastim in preventing neutropenia in gastrointestinal patients receiving the chemotherapy, including S-1/capecitabine-based regimens or the fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) regimens. METHOD: Five hundred and sixty-one gastrointestinal patients from 40 sites across China, between May 2019 and November 2021, were included. The administration of mecapegfilgrastim was prescribed at the discretion of local physicians. RESULTS: The most common adverse drug reactions (ADRs) of any grade for all patients was increased white blood cells (2.9%). Grade 3/4 ADRs were observed for anemia (0.2%), decreased white blood cells (0.2%), and decreased neutrophil count (0.2%). Among the 116 patients who received S-1/capecitabine-based chemotherapy throughout all cycles, ADRs of any grade included anemia (1.7%), myalgia (0.9%), and increased alanine aminotransferase (0.9%). No grade 3/4 ADRs were observed. In 414 cycles of patients who underwent S-1/capecitabine-based regimens, only one (0.2%) cycle experienced grade 4 neutropenia. In the FO...